Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2020

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Résumé

Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional characteristics of TP53 mutant are heterogeneous, as reflected in multiple functional TP53 classifications and their impact in patients treated with azacitidine is less clear. We analyzed the therapeutic course and outcome of 279 patients treated with azacitidine between 2007 and 2016, prospectively enrolled in our regional healthcare network. By screening 224 of them, we detected TP53 mutations in 55 patients (24.6%), including 53 patients (96.4%) harboring high-risk cytogenetics. The identification of any TP53 mutation was associated with worse overall survival but not with response to azacitidine in the whole cohort and in the subgroup of patients with adverse karyotype. Stratification of patients according to three recent validated functional classifications did not allow the identification of TP53 mutated patients who could benefit from azacitidine. Systematic TP53 mutant classification will deserve further exploration in the setting of patients treated with conventional therapy and in the emerging field of therapies targeting TP53 pathway.
Fichier principal
Vignette du fichier
islandora_141485.pdf (1.1 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04500362 , version 1 (11-03-2024)

Identifiants

Citer

Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, et al.. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PLoS ONE, 2020, 15 (10), pp.e0238795. ⟨10.1371/journal.pone.0238795⟩. ⟨hal-04500362⟩
7 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More